MESOBLAST LIMITED - Announcements

Market Cap $1.044B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based is developing a range of late-stage product... Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

MSB	Appendix 3Y for Jane Bell		16/04/24	171.94KB	Share
MSB	Application for quotation of securities - MSB		16/04/24	17.59KB	Share
MSB	Notification regarding unquoted securities - MSB		16/04/24	15.92KB	Share
MSB	Notification of cessation of securities - MSB		15/04/24	12.8KB	Share
MSB	Change in substantial holding		09/04/24	2.01MB	Share
MSB	Change in substantial holding		02/04/24	1.06MB	Share
MSB	FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA	PRICE SENSITIVE	26/03/24	159.39KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	26/03/24	114KB	Share
MSB	Cleansing Notice		26/03/24	108.36KB	Share
MSB	Application for quotation of securities - MSB		22/03/24	14.19KB	Share
MSB	Change in substantial holding		20/03/24	1.37MB	Share
MSB	Proposed issue of securities - MSB		20/03/24	14.8KB	Share
MSB	Cleansing Notice		19/03/24	227.96KB	Share
MSB	Appendix 2A		18/03/24	344.46KB	Share
MSB	Proposed issue of securities - MSB		14/03/24	15.09KB	Share
MSB	Mesoblast Completes Placement and Entitlement Offer	PRICE SENSITIVE	14/03/24	159.66KB	Share
MSB	FDA Supports Accelerated Approval Pathway for Heart Failure	PRICE SENSITIVE	11/03/24	183.32KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	29/02/24	486.32KB	Share
MSB	Half Year Financial Results Presentation	PRICE SENSITIVE	29/02/24	1.7MB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	29/02/24	1.66MB	Share
MSB	Mesoblast 2024 Half Year Financial Results Webcast		26/02/24	113.58KB	Share
MSB	FDA Grants Orphan Drug Designation for Revascor	PRICE SENSITIVE	15/02/24	176.6KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	423.11KB	Share
MSB	FDA Grants Rare Pediatric Disease Designation for Revascor	PRICE SENSITIVE	19/01/24	181.5KB	Share
MSB	App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina		15/01/24	339.51KB	Share
MSB	Notification regarding unquoted securities - MSB		15/01/24	27.4KB	Share
MSB	Notification of cessation of securities - MSB		15/01/24	23.21KB	Share
MSB	Appendix 3Y for Joseph Swedish		03/01/24	213.56KB	Share
MSB	Amended Appendix 3Gs for Unquoted Warrants		03/01/24	814.1KB	Share
MSB	Update on Institutional Placement and Entitlement Offer		28/12/23	139.29KB	Share
MSB	Appendix 3Ys- J Swedish,B Burns,J Bell,P Krause,P Facchina		28/12/23	525.98KB	Share
MSB	Appendix 2A		28/12/23	347.15KB	Share
MSB	Notification of cessation of securities - MSB		28/12/23	21.55KB	Share
MSB	Change of Director's Interest Notice - Silviu Itescu		12/12/23	199.23KB	Share
MSB	Institutional Placement Cleansing Notice		12/12/23	263.86KB	Share
MSB	Appendix 2A		11/12/23	375.53KB	Share
MSB	Information For Retail Shareholders	PRICE SENSITIVE	08/12/23	2.54MB	Share
MSB	Mesoblast Completes Institutional Allocation	PRICE SENSITIVE	05/12/23	197.91KB	Share
MSB	Entitlement Offer Cleansing Notice		04/12/23	168.57KB	Share
MSB	Appendix 3B Entitlement Offer and Placement		04/12/23	694.03KB	Share
MSB	Entitlement Offer and Placement Investor Presentation	PRICE SENSITIVE	04/12/23	2.06MB	Share
MSB	MSB Launches Entitlement Offer and Placement	PRICE SENSITIVE	04/12/23	292.56KB	Share
MSB	Trading Halt	PRICE SENSITIVE	01/12/23	217.16KB	Share
MSB	Amended Constitution		29/11/23	915.58KB	Share
MSB	Results of Meeting		28/11/23	187.13KB	Share
MSB	CEO Presentation to 2023 Annual General Meeting		28/11/23	1.89MB	Share
MSB	Mesoblast Chairman Message to 2023 AGM		28/11/23	181.09KB	Share
MSB	MSB Files for FDA Designations in Congenital Heart Disease		27/11/23	191.4KB	Share
MSB	Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial		22/11/23	174.07KB	Share
MSB	Mesoblast Corporate Presentation		15/11/23	1.68MB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	398.85KB	Share
MSB	Annual Report to Shareholders		30/10/23	3.92MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		30/10/23	471.69KB	Share
MSB	Appendix 4G and Corporate Governance Statement		30/10/23	473.72KB	Share
MSB	Notification of cessation of securities - MSB		16/10/23	22.14KB	Share
MSB	Notification regarding unquoted securities - MSB		16/10/23	25.52KB	Share
MSB	Final Director's Interest Notice		29/09/23	289.13KB	Share
MSB	Jane Bell Appointed Chair of Audit and Risk Committee		26/09/23	133KB	Share
MSB	Mesoblast Type A Meeting with FDA		21/09/23	180.71KB	Share
MSB	MSB Annual Financial Results and Operational Update	PRICE SENSITIVE	31/08/23	430.53KB	Share
MSB	Annual Financial Results Presentation		31/08/23	1.55MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	31/08/23	2.9MB	Share
MSB	Mesoblast 2023 Full Year Financial Results Webcast		29/08/23	113.86KB	Share
MSB	Change in substantial holding		29/08/23	982.31KB	Share
MSB	Ceasing to be a substantial holder		11/08/23	386.68KB	Share
MSB	Ceasing to be a substantial holder		10/08/23	382.31KB	Share
MSB	Change in substantial holding		10/08/23	477.4KB	Share
MSB	Change in substantial holding		09/08/23	463.15KB	Share
MSB	Change in substantial holding		09/08/23	481.52KB	Share
MSB	Update on BLA for Graft Versus Host Disease	PRICE SENSITIVE	04/08/23	178.56KB	Share
MSB	Change in substantial holding		03/08/23	560.83KB	Share
MSB	Trading Halt	PRICE SENSITIVE	02/08/23	195.14KB	Share
MSB	Change in substantial holding		01/08/23	538.92KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/23	401.67KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Ys		07/07/23	566.38KB	Share
MSB	Change of Director's Interest Notice		13/06/23	259.12KB	Share
MSB	Mesoblast Director Appointed to Strategic Advisory Role		05/06/23	161.1KB	Share
MSB	MSB Reports Q3 Financial Results and Operational Highlights	PRICE SENSITIVE	26/05/23	402.9KB	Share
MSB	Third Quarter Results Presentation		26/05/23	1.76MB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	26/05/23	591.58KB	Share
MSB	Mesoblast Third Quarter Financial Results Webcast		24/05/23	114.98KB	Share
MSB	Becoming a substantial holder		03/05/23	842.89KB	Share
MSB	Change in substantial holding		03/05/23	245.59KB	Share
MSB	Cleansing Notice		01/05/23	232.25KB	Share
MSB	Application for quotation of securities - MSB		28/04/23	23.26KB	Share
MSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	416.6KB	Share
MSB	Reinstatement to Official Quotation	PRICE SENSITIVE	26/04/23	86.01KB	Share
MSB	Proposed issue of securities - MSB		26/04/23	24.49KB	Share
MSB	Mesoblast Completes Private Placement	PRICE SENSITIVE	26/04/23	169.21KB	Share
MSB	Voluntary Suspension	PRICE SENSITIVE	24/04/23	281.47KB	Share
MSB	Trading Halt	PRICE SENSITIVE	20/04/23	281.84KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	20/04/23	115.82KB	Share
MSB	FDA Schedules GvHD Pre-License Manufacturing Inspection		22/03/23	187.07KB	Share
MSB	Appendix 3G and Appendix 3H		15/03/23	652.68KB	Share
MSB	FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L	PRICE SENSITIVE	08/03/23	195.02KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	08/03/23	114.29KB	Share
MSB	Prospectus for Warrants Related to Oaktree Facility		03/03/23	509.39KB	Share
MSB	DREAM HF Trial Published in JACC	PRICE SENSITIVE	28/02/23	226.95KB	Share
MSB	MSB Q2 Financial Results and Operational Highlights	PRICE SENSITIVE	28/02/23	408.95KB	Share
MSB	Second Quarter Results Presentation		28/02/23	1.57MB	Share

MSB Appendix 3Y for Jane Bell
16/04/24		171.94KB	Share
MSB Application for quotation of securities - MSB
16/04/24		17.59KB	Share
MSB Notification regarding unquoted securities - MSB
16/04/24		15.92KB	Share
MSB Notification of cessation of securities - MSB
15/04/24		12.8KB	Share
MSB Change in substantial holding
09/04/24		2.01MB	Share
MSB Change in substantial holding
02/04/24		1.06MB	Share
MSB FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
26/03/24	PRICE SENSITIVE	159.39KB	Share
MSB Pause in Trading
26/03/24	PRICE SENSITIVE	114KB	Share
MSB Cleansing Notice
26/03/24		108.36KB	Share
MSB Application for quotation of securities - MSB
22/03/24		14.19KB	Share
MSB Change in substantial holding
20/03/24		1.37MB	Share
MSB Proposed issue of securities - MSB
20/03/24		14.8KB	Share
MSB Cleansing Notice
19/03/24		227.96KB	Share
MSB Appendix 2A
18/03/24		344.46KB	Share
MSB Proposed issue of securities - MSB
14/03/24		15.09KB	Share
MSB Mesoblast Completes Placement and Entitlement Offer
14/03/24	PRICE SENSITIVE	159.66KB	Share
MSB FDA Supports Accelerated Approval Pathway for Heart Failure
11/03/24	PRICE SENSITIVE	183.32KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
29/02/24	PRICE SENSITIVE	486.32KB	Share
MSB Half Year Financial Results Presentation
29/02/24	PRICE SENSITIVE	1.7MB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
29/02/24	PRICE SENSITIVE	1.66MB	Share
MSB Mesoblast 2024 Half Year Financial Results Webcast
26/02/24		113.58KB	Share
MSB FDA Grants Orphan Drug Designation for Revascor
15/02/24	PRICE SENSITIVE	176.6KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	423.11KB	Share
MSB FDA Grants Rare Pediatric Disease Designation for Revascor
19/01/24	PRICE SENSITIVE	181.5KB	Share
MSB App 3Ys S Itescu,E Rose,J Swedish,B Burns,J Bell,P Facchina
15/01/24		339.51KB	Share
MSB Notification regarding unquoted securities - MSB
15/01/24		27.4KB	Share
MSB Notification of cessation of securities - MSB
15/01/24		23.21KB	Share
MSB Appendix 3Y for Joseph Swedish
03/01/24		213.56KB	Share
MSB Amended Appendix 3Gs for Unquoted Warrants
03/01/24		814.1KB	Share
MSB Update on Institutional Placement and Entitlement Offer
28/12/23		139.29KB	Share
MSB Appendix 3Ys- J Swedish,B Burns,J Bell,P Krause,P Facchina
28/12/23		525.98KB	Share
MSB Appendix 2A
28/12/23		347.15KB	Share
MSB Notification of cessation of securities - MSB
28/12/23		21.55KB	Share
MSB Change of Director's Interest Notice - Silviu Itescu
12/12/23		199.23KB	Share
MSB Institutional Placement Cleansing Notice
12/12/23		263.86KB	Share
MSB Appendix 2A
11/12/23		375.53KB	Share
MSB Information For Retail Shareholders
08/12/23	PRICE SENSITIVE	2.54MB	Share
MSB Mesoblast Completes Institutional Allocation
05/12/23	PRICE SENSITIVE	197.91KB	Share
MSB Entitlement Offer Cleansing Notice
04/12/23		168.57KB	Share
MSB Appendix 3B Entitlement Offer and Placement
04/12/23		694.03KB	Share
MSB Entitlement Offer and Placement Investor Presentation
04/12/23	PRICE SENSITIVE	2.06MB	Share
MSB MSB Launches Entitlement Offer and Placement
04/12/23	PRICE SENSITIVE	292.56KB	Share
MSB Trading Halt
01/12/23	PRICE SENSITIVE	217.16KB	Share
MSB Amended Constitution
29/11/23		915.58KB	Share
MSB Results of Meeting
28/11/23		187.13KB	Share
MSB CEO Presentation to 2023 Annual General Meeting
28/11/23		1.89MB	Share
MSB Mesoblast Chairman Message to 2023 AGM
28/11/23		181.09KB	Share
MSB MSB Files for FDA Designations in Congenital Heart Disease
27/11/23		191.4KB	Share
MSB Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial
22/11/23		174.07KB	Share
MSB Mesoblast Corporate Presentation
15/11/23		1.68MB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	398.85KB	Share
MSB Annual Report to Shareholders
30/10/23		3.92MB	Share
MSB Notice of Annual General Meeting and Proxy Form
30/10/23		471.69KB	Share
MSB Appendix 4G and Corporate Governance Statement
30/10/23		473.72KB	Share
MSB Notification of cessation of securities - MSB
16/10/23		22.14KB	Share
MSB Notification regarding unquoted securities - MSB
16/10/23		25.52KB	Share
MSB Final Director's Interest Notice
29/09/23		289.13KB	Share
MSB Jane Bell Appointed Chair of Audit and Risk Committee
26/09/23		133KB	Share
MSB Mesoblast Type A Meeting with FDA
21/09/23		180.71KB	Share
MSB MSB Annual Financial Results and Operational Update
31/08/23	PRICE SENSITIVE	430.53KB	Share
MSB Annual Financial Results Presentation
31/08/23		1.55MB	Share
MSB Preliminary Final Report including Appendix 4E
31/08/23	PRICE SENSITIVE	2.9MB	Share
MSB Mesoblast 2023 Full Year Financial Results Webcast
29/08/23		113.86KB	Share
MSB Change in substantial holding
29/08/23		982.31KB	Share
MSB Ceasing to be a substantial holder
11/08/23		386.68KB	Share
MSB Ceasing to be a substantial holder
10/08/23		382.31KB	Share
MSB Change in substantial holding
10/08/23		477.4KB	Share
MSB Change in substantial holding
09/08/23		463.15KB	Share
MSB Change in substantial holding
09/08/23		481.52KB	Share
MSB Update on BLA for Graft Versus Host Disease
04/08/23	PRICE SENSITIVE	178.56KB	Share
MSB Change in substantial holding
03/08/23		560.83KB	Share
MSB Trading Halt
02/08/23	PRICE SENSITIVE	195.14KB	Share
MSB Change in substantial holding
01/08/23		538.92KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
31/07/23	PRICE SENSITIVE	401.67KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Ys
07/07/23		566.38KB	Share
MSB Change of Director's Interest Notice
13/06/23		259.12KB	Share
MSB Mesoblast Director Appointed to Strategic Advisory Role
05/06/23		161.1KB	Share
MSB MSB Reports Q3 Financial Results and Operational Highlights
26/05/23	PRICE SENSITIVE	402.9KB	Share
MSB Third Quarter Results Presentation
26/05/23		1.76MB	Share
MSB Third Quarter Financial Results on Form 6-K
26/05/23	PRICE SENSITIVE	591.58KB	Share
MSB Mesoblast Third Quarter Financial Results Webcast
24/05/23		114.98KB	Share
MSB Becoming a substantial holder
03/05/23		842.89KB	Share
MSB Change in substantial holding
03/05/23		245.59KB	Share
MSB Cleansing Notice
01/05/23		232.25KB	Share
MSB Application for quotation of securities - MSB
28/04/23		23.26KB	Share
MSB Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	416.6KB	Share
MSB Reinstatement to Official Quotation
26/04/23	PRICE SENSITIVE	86.01KB	Share
MSB Proposed issue of securities - MSB
26/04/23		24.49KB	Share
MSB Mesoblast Completes Private Placement
26/04/23	PRICE SENSITIVE	169.21KB	Share
MSB Voluntary Suspension
24/04/23	PRICE SENSITIVE	281.47KB	Share
MSB Trading Halt
20/04/23	PRICE SENSITIVE	281.84KB	Share
MSB Pause in Trading
20/04/23	PRICE SENSITIVE	115.82KB	Share
MSB FDA Schedules GvHD Pre-License Manufacturing Inspection
22/03/23		187.07KB	Share
MSB Appendix 3G and Appendix 3H
15/03/23		652.68KB	Share
MSB FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
08/03/23	PRICE SENSITIVE	195.02KB	Share
MSB Pause in Trading
08/03/23	PRICE SENSITIVE	114.29KB	Share
MSB Prospectus for Warrants Related to Oaktree Facility
03/03/23		509.39KB	Share
MSB DREAM HF Trial Published in JACC
28/02/23	PRICE SENSITIVE	226.95KB	Share
MSB MSB Q2 Financial Results and Operational Highlights
28/02/23	PRICE SENSITIVE	408.95KB	Share
MSB Second Quarter Results Presentation
28/02/23		1.57MB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 91.5¢		Change 0.015(1.67%)		Mkt cap ! $1.044B

Open	High	Low	Value	Volume
92.0¢	93.5¢	89.0¢	$6.949M	7.616M

Buyers (Bids)

No.	Vol.	Price($)
1	6000	91.0¢

Sellers (Offers)

Price($)	Vol.	No.
92.0¢	134540	9

View Market Depth

No.	Vol.	Price($)
1	6000	0.910
2	79859	0.905
7	28345	0.900
4	23870	0.895
5	76036	0.890

Price($)	Vol.	No.
0.920	134540	9
0.925	37000	2
0.930	110126	10
0.935	247065	8
0.940	48462	7

Last trade - 16.10pm 25/04/2024 (20 minute delay)


Last 90.5¢		Change 0.015 ( 0.33 %)
Open	High	Low	Volume
91.0¢	93.5¢	89.0¢	1824946
Last updated 15.59pm 25/04/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories